advertising
-
2
Sibaud V, Dalenc F, Chevreau C, et al: HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16: 1469, 2011.
-
3
Miller KK, Gorcey L, McLellan BN: Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71: 787, 2014.
-
4
McLellan B, Ciardiello F, Lacouture ME, et al: Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26: 2017, 2015.
-
5
Macdonald JB, Macdonald B, Golitz LE, et al: Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72: 203, 2015.
-
6
Gomez P, Lacouture ME: Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16: 1508, 2011.
-
7
Nagel MPM, Kopsky DJ, Lacouture ME, et al: Foot care in oncology: the cancer patient from ankle to toe. The ASCO Post. Available at: http://www.ascopost.com/issues/december-10-2015/foot-care-in-oncology-the-cancer-patient-from-ankle-to-toe/. Accessed.
-
8
Hausheer FH, Schilsky RL, Bain S, et al: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33: 15, 2006.
-
9
Schneider BP, Hershman DL, Loprinzi C: Symptoms: chemotherapy-induced peripheral neuropathy. Adv Exp Med Biol 862: 77, 2015.
-
10
Smith EM, Bridges CM, Kanzawa G, et al: Cancer treatment-related neuropathic pain syndromes—epidemiology and treatment: an update. Curr Pain Headache Rep 18: 459, 2014.
-
11
Cavaletti G, Alberti P, Marmiroli P: Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book e553, 2015.
-
12
Tofthagen C, Donovan KA, Morgan MA, et al: Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21: 3307, 2013.
-
13
Park HJ: Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol 67: 4, 2014.
-
14
Zedan AH, Vilholm OJ: Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 115: 193, 2014.
-
15
Lavoie Smith EM, Barton DL, Qin R, et al: Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22: 2787, 2013.
-
16
Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13: 741, 2003.
-
17
Bouhassira D, Attal N, Fermanian J, et al: Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108: 248, 2004.
-
18
Smith EM, Pang H, Cirrincione C, et al: Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309: 1359, 2013.
-
19
Durand JP, Deplanque G, Montheil V, et al: Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23: 200, 2012.
-
20
Barton DL, Wos EJ, Qin R, et al: A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19: 833, 2011.
-
21
Marshall TF. Effects of chemotherapy-induced-peripheral-neuropathy on spatiotemporal gait parameters and fall risk in cancer patients after the completion of chemotherapy drug treatment (dissertation). Seton Hall University Dissertations and Theses, Seton Hall, NJ, 2016.
-
22
Streckmann F, Kneis S, Leifert JA, et al: Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 25: 493, 2014.
-
23
Streckmann F, Zopf EM, Lehmann HC, et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44: 1289, 2014.
-
24
Lopez Lopez D, Losa Iglesias ME, Becerro de Bengoa Vallejo R, et al: Optimal choice of footwear in the elderly population. Geriatr Nurs 36: 458, 2015.
-
25
Paton JS, Roberts A, Bruce GK, et al: Does footwear affect balance?: the views and experiences of people with diabetes and neuropathy who have fallen. JAPMA 103: 508, 2013.
-
26
von Moos R, Thuerlimann BJ, Aapro M, et al: Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44: 781, 2008.
-
27
Heidary N, Naik H, Burgin S: Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58: 545, 2008.
-
28
Anderson R, Jatoi A, Robert C, et al: Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 14: 291, 2009.
-
29
Fischer A, Wu S, Ho AL, et al: The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 31: 787, 2013.
-
30
Dranitsaris G, Vincent MD, Yu J, et al: Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 23: 2103, 2012.
-
31
Balagula Y, Wu S, Su X, et al: The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30: 1773, 2012.
-
32
Lacouture ME, Wu S, Robert C, et al: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13: 1001, 2008.
-
33
Lacouture ME, Reilly LM, Gerami P, et al: Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19: 1955, 2008.
-
34
Lorusso D, Di Stefano A, Carone V, et al: Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot' syndrome). Ann Oncol 18: 1159, 2007.
-
35
Ren Z, Zhu K, Kang H, et al: Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33: 894, 2015.
-
36
Ionescu MA, Fabbrocini G, Cristaudo A, et al: Topical nonocclusive polymers in hand-foot skin reaction. J Am Acad Dermatol 72: AB65, 2013.
-
37
Capriotti K, Capriotti JA, Lessin S, et al: The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 173: 842, 2015.
-
38
Robert C, Sibaud V, Mateus C, et al: Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16: 71133, 2015.
-
39
Garden BC, Wu S, Lacouture ME: The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 67: 400, 2012.
-
40
Scotte F, Banu E, Medioni J, et al: Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112: 1625, 2008.
-
41
Lomax A, Thornton J, Singh D: Toenail paronychia. Foot Ankle Surg 22: 219, 2016.
-
42
Frain-Bell W: Chronic paronychia. Short review of 590 cases. Trans St John's Hosp Dermatol Soc 38: 29, 1957.
-
43
Capriotti K, Capriotti JA: Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation. Clin Cosmet Investig Dermatol 8: 489, 2015.
-
44
Goto H, Yoshikawa S, Mori K, et al: Effective treatments for paronychia caused by oncology pharmacotherapy. J Dermatol 43: 670, 2016.
-
45
Fliegelman MT, Lafayette GO: How we treat paronychia. Postgrad Med 48: 267, 1970.
-
46
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19: 1079, 2011.
-
47
Lacouture ME, Maitland ML, Segaert S, et al: A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18: 509, 2010.
-
48
D'Angelo SP, Kris MG, Pietanza MC, et al: A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. J Thorac Oncol 6: 624, 2011.
Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors
Awareness, Education, and Literature Review
Search for other papers by Mario E. Lacouture in
Current site
Google Scholar
PubMed
Search for other papers by David J. Kopsky in
Current site
Google Scholar
PubMed
Search for other papers by Raphael Lilker in
Current site
Google Scholar
PubMed
Search for other papers by Fiona Damstra in
Current site
Google Scholar
PubMed
Search for other papers by Mecheline H.M. van der Linden in
Current site
Google Scholar
PubMed
Search for other papers by Azael Freites-Martinez in
Current site
Google Scholar
PubMed
Search for other papers by Mischa P.M. Nagel in
Current site
Google Scholar
PubMed
Cancer is one of the leading causes of mortality and morbidity worldwide. Recent improved therapies have resulted in more patients surviving cancer and living longer. Despite these advances, the majority of patients will develop adverse events from anticancer therapies. Foot alterations, including nail toxicities, hand-foot syndrome, edema, xerosis, hyperkeratosis, and neuropathy, are frequent among cancer patients. These untoward conditions may negatively impact quality of life, and in some cases may result in the interruption or discontinuation of cancer treatments. Appropriate prevention, diagnosis, and management of podiatric adverse events are essential to maintain foot function and health-related quality of life, both of which are critical for the care of cancer patients and survivors. This article shows results related to complaint and impact on quality of life of the Oncology Foot Care program and reviews publications specific to podiatric adverse events related to cancer treatments.
advertising
